GlobeNewswire: PolyMedix, Inc. Contains the last 10 of 41 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T12:27:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2013/03/15/531117/10025362/en/PolyMedix-Announces-Results-of-Special-Meeting-Effective-Date-of-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=13275PolyMedix Announces Results of Special Meeting, Effective Date of Reverse Stock Split2013-03-15T17:55:05Z<![CDATA[RADNOR, Pa., March 15, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company developing small-molecule drugs designed to mimic the activity of host defense proteins (HDPs) for the treatment of infectious diseases and innate immune disorders, today announced that its stockholders voted overwhelmingly to approve a reverse stock split of the company's common stock at a ratio of up to fifty-for-one. The company's board of directors subsequently fixed the reverse stock split ratio at fifty-for-one and fixed the record date for the reverse stock split.]]>https://www.globenewswire.com/news-release/2013/03/07/529103/10024472/en/PolyMedix-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=13275PolyMedix Announces Proposed Public Offering of Common Stock2013-03-07T21:12:40Z<![CDATA[RADNOR, Pa., March 7, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company developing small-molecule drugs designed to mimic the activity of host defense proteins (HDPs) for the treatment of infectious diseases and innate immune disorders, today announced that it plans to raise approximately $25 million through a public offering of its common stock. The company intends to grant the underwriters a 45-day option to purchase up to 15% in additional shares to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2013/03/06/528523/10024214/en/PolyMedix-Provides-Business-Update-and-Reports-Fourth-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=13275PolyMedix Provides Business Update and Reports Fourth Quarter 2012 Financial Results2013-03-06T12:00:00Z<![CDATA[RADNOR, Pa., March 6, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company developing small-molecule drugs designed to mimic the activity of host defense proteins (HDPs) for the treatment of infectious diseases and innate immune disorders, today provided a business update and announced its financial results for the fourth quarter and year ended December 31, 2012.]]>https://www.globenewswire.com/news-release/2013/02/07/521776/10021026/en/PolyMedix-CEO-Posts-Letter-to-Shareholders-on-Its-Website.html?f=22&fvtc=4&fvtv=13275PolyMedix CEO Posts Letter to Shareholders on Its Website2013-02-07T13:00:00Z<![CDATA[RADNOR, Pa., Feb. 7, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs based on its novel defensin-mimetic technology platform, today announced that Edward Smith, its newly appointed interim Chief Executive Officer, posted to its website a letter to shareholders. This communication can be found ]]>https://www.globenewswire.com/news-release/2013/01/30/519681/10020001/en/PolyMedix-Announces-Departure-of-CEO-Appointment-of-Interim-CEO.html?f=22&fvtc=4&fvtv=13275PolyMedix Announces Departure of CEO, Appointment of Interim CEO2013-01-30T21:30:00Z<![CDATA[RADNOR, Pa., Jan. 30, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobials, today announced that Nicholas Landekic's employment with the company has ceased and that he will be pursuing other interests. Mr. Landekic was the company's president and chief executive officer and Edward F. Smith, who has served as the company's chief financial officer since January 2006, has been appointed as the interim president and chief executive officer.]]>https://www.globenewswire.com/news-release/2013/01/23/518092/10019036/en/PolyMedix-Engages-Investment-Banker-Amends-Credit-Facility.html?f=22&fvtc=4&fvtv=13275PolyMedix Engages Investment Banker, Amends Credit Facility2013-01-23T21:30:00Z<![CDATA[RADNOR, Pa., Jan. 23, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs intended to treat patients with serious acute-care conditions, today announced that it has engaged Canaccord Genuity Inc. as its financial advisor to review and assist with the company's strategic and financial alternatives, including a licensing transaction around its lead antibiotic compound, brilacidin, or a potential sale of the company or its assets. PolyMedix continues to work with its financing advisors on a financing transaction that could permit the company to remain independent and continue the clinical development of brilacidin. As previously reported, the company's cash and investment balances are not sufficient to fund any new clinical trials and the company has implemented a plan to reduce costs and resulting cash outflows, including scaling back operations, personnel reductions, and deferrals and reductions in compensation.]]>https://www.globenewswire.com/news-release/2013/01/14/516202/10017962/en/PolyMedix-Defensin-Mimetic-Anti-Malaria-Data-Published-in-Cell-Host-and-Microbe.html?f=22&fvtc=4&fvtv=13275PolyMedix Defensin-Mimetic Anti-Malaria Data Published in Cell Host and Microbe2013-01-14T12:00:00Z<![CDATA[RADNOR, Pa., Jan. 14, 2013 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobial agents, today announced that pre-clinical data demonstrating activity of the Company's defensin-mimetic antimicrobial compounds against the parasite that causes malaria, ]]>https://www.globenewswire.com/news-release/2012/11/16/505816/10012917/en/PolyMedix-Announces-Successful-Meeting-With-FDA-for-Brilacidin.html?f=22&fvtc=4&fvtv=13275PolyMedix Announces Successful Meeting With FDA for Brilacidin2012-11-16T13:32:15Z<![CDATA[Meeting With FDA Provides Guidance for U.S.-Based Phase 2B Clinical Trial, Including Use of Single-Dose and Three-Day Dosing Regimens RADNOR, Pa., Nov. 16, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobial agents, today announced that it had a Type B meeting with the Division of Anti-Infective Products of the United States Food and Drug Administration (FDA). As a result of the meeting, PolyMedix has direction with respect to the design and conduct of its planned Phase 2B dose-optimization clinical trial using brilacidin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by ]]>https://www.globenewswire.com/news-release/2012/11/08/503811/10011851/en/PolyMedix-Reports-Third-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=13275PolyMedix Reports Third Quarter 2012 Financial Results2012-11-08T21:36:58Z<![CDATA[RADNOR, Pa., Nov. 8, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to transforming the treatment of infectious diseases with novel defensin-mimetic antimicrobials, today announced its financial results for the third quarter ended September 30, 2012 and provided an update on recent key events.]]>https://www.globenewswire.com/news-release/2012/09/19/491571/10005471/en/PolyMedix-Receives-Grant-From-National-Cancer-Institute-to-Study-Brilacidin-for-Oral-Mucositis.html?f=22&fvtc=4&fvtv=13275PolyMedix Receives Grant From National Cancer Institute to Study Brilacidin for Oral Mucositis2012-09-19T11:00:00Z<![CDATA[RADNOR, Pa., Sept. 19, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative antimicrobial compounds intended to treat a wide range of infectious diseases and other conditions, today announced that it has received a Phase I grant from the National Cancer Institute Division of the National Institutes of Health (NIH) to further explore the profile and properties of its defensin-mimetic compound, brilacidin, in treating oral mucositis. ]]>